National’s Covid-19 Plan, ‘Opening Up’ includes a strong priority on improving our hospitals, expanding our ICU capacity
and funding treatments for Covid-19, National’s Health spokesperson Dr Shane Reti and Associate Health spokesperson
Simon Watts say.
Dr Reti says New Zealanders did the hard yards last year to stamp out Covid-19 and expected the Government to invest
wisely in the health system to prepare it for future outbreaks.
“Instead of investing in ICU capacity, the Government frittered the Covid-19 Response Fund away and has focused on
restructuring the entire health system in the middle of a global pandemic.
“The number of ICU beds has actually fallen since the end of April 2020 through to September 2021, no new ICU bed spaces
have been provisioned since Delta first appeared in MIQ and urgent alterations had to be made at the start of the recent
outbreak to hospital wards in Auckland.
“In the first three weeks of the recent outbreak 62,829 inpatient procedures were cancelled. A delayed procedure can
have a significant impact on a person’s health and their ability to recover once the surgery does proceed. In some
cases, delaying a procedure is putting a life at risk,” Dr Reti says.
Mr Watts says National’s plan involves urgently implementing a specialist healthcare workforce migration plan.
“We would select the 3000 doctors and nurses out of the expression of interest pool and process them urgently. We would
also prioritise and fast-track resident applications for critical healthcare workers, setting aside dedicated MIQ spaces
if required.
“National would offer conditional residence class visas upon arrival to specialist, experienced nurses who have the
qualifications and experience needed to immediately start working in New Zealand.
“We would also fast-track the building of new hospital wards to increase bed capacity. In Auckland, there are business
cases for projects at Waitakere Hospital that could be progressed immediately,” Mr Watts says.
National’s Plan also invests in next generation Covid-19 treatments.
New Zealand is now well behind other countries in approving and ordering exciting new Covid-19 treatments like Ronapreve
and Sotrovimab. These monoclonal antibody treatments are used to treat Covid-19 and have shown real promise in clinical
trials.
“Ronapreve has been licensed for use in 20 countries and the EU has bought 55,000 doses. Sotrovimab has just been
approved for use in Australia, which has bought 7700 doses,” Dr Reti says.
“New Zealand has not bought any doses of either treatment or approved them for use.
“National would establish a ring-fenced and dedicated Covid-19 Treatment fund from within the Covid-19 Response fund,
and task Pharmac with negotiating purchase agreements with a variety of manufacturers,” Dr Reti says.
“National wants New Zealanders to enjoy more of the freedoms they have before the pandemic hit. To do this we must make
sure our health system is robust enough to both deal with people who may fall ill with Covid-19 and continue day-to-day
operations,” Mr Watts says.